[Express Train - Episode 66] LabGenomics, Developer of COVID-19 Diagnostic Kits

LabGenomics is a molecular diagnostic service development company. It holds the largest experimental data in Korea in the fields of cancer gene and urogenital infection pathogen analysis. By manufacturing various kits required for testing in-house, it also secures price competitiveness through cost reduction.

LabGenomics received a request from the U.S. Food and Drug Administration (FDA) to apply for Emergency Use Authorization for its novel coronavirus (COVID-19) diagnostic kit. The company plans to officially sell the product in the U.S. after obtaining FDA approval. LabGenomics is currently coordinating meeting schedules with the U.S. Centers for Disease Control and Prevention (CDC) regarding the diagnostic kit. The diagnostic kit developed by LabGenomics (LabGun COVID-19 Assay) is based on real-time polymerase chain reaction (RT-PCR) technology.

Patent attorney Um Jeonghan from BLT Patent Law Firm reviewed the patent and trademark application status of LabGenomics.

Publicly listed companies on the domestic stock market disclose patent acquisition information through the Financial Supervisory Service’s electronic disclosure system. However, many stock investors tend to overlook patent disclosures.

Not only patents but also trademark registrations serve as important indicators for understanding future corporate value, as they signal the direction a listed company is heading. Some patent disclosures even act as direct triggers for stock price increases.

It is not easy for general investors to assess the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy is reviewing the patent and trademark application statuses of listed companies together with patent attorney Um Jeonghan from BLT Patent Law Firm through the program "Express Train."

"Express Train" is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.